Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Opdivo Outdistances Keytruda in 2022 with Sales Up 30 Billion Yen YOY: Encise
January 20, 2023
- Ex-Sandoz Japan Chief Tapped to Spearhead Nichi-Iko Turnaround
January 18, 2023
- Shionogi Commences New COVID Vaccine Trials for Children
January 18, 2023
- Chiome, China Firm Call off License Deal for Anti-TROP-2 Antibodies
January 18, 2023
- Chugai to End Sale of Joint Function Improving Agent Suvenyl in Japan
January 17, 2023
- Towa Set to Take on Legal Battle over Treakisym Patent
January 17, 2023
- Toray Rolls Out Remitch OD Tablets in South Korea
January 17, 2023
- Alzheimer’s Med Lecanemab Submitted in Japan: Eisai
January 16, 2023
- Daiichi Sankyo Files First Home-Developed mRNA COVID Vaccine in Japan
January 16, 2023
- Estimated 11,867 Patients Given Xocova as of Jan. 5: Shionogi
January 16, 2023
- Ono, Monash University Ink GPCR Antibody Deal
January 16, 2023
- Skyrizi’s New IV Form Now Available for Crohn’s Disease
January 16, 2023
- Lucentis Biosimilar Now Approved for Diabetic Macular Edema
January 16, 2023
- Takeda’s Exkivity Approved in China for EGFR Exon 20+ NSCLC
January 16, 2023
- RaQualia’s Acid Reducer Tegoprazan Approved in Singapore
January 16, 2023
- Zeria’s Acinon Now Sole Nizatidine Product Being Shipped as Yoshindo Launches Recall
January 13, 2023
- Janssen Vows to Offer New Positions for Employees Shown Exit Door: 1st Labor Talks
January 13, 2023
- Ferring to Take Over Gonax’s Japan Authorization from Astellas
January 13, 2023
- Xofluza Adds Pediatric Indication in Europe: Roche
January 13, 2023
- Alfresa Sets Up Regenerative Medicine Unit to Supply Master Cells, Eyes Distribution
January 12, 2023
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…